bullish
WuXi AppTec (2359.HK) - The Certainties and the Uncertainties
252 Views03 Jun 2021 08:56
As the benchmark company in China CRO/CDMO industry, WuXi AppTec is always the focus of investors. This insight mainly analyzed the certainties and uncertainties of the Company and business outlook.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (July.9)11 Jul 2021
- Pre-IPO Novotech Holdings - The Future Would Not Be Easy06 Jul 2021
- Hansoh Pharmaceutical (3692.HK) - Insights on Core Products, Pipeline, Catalysts and Key Risks14 Jun 2021
- WuXi AppTec (2359.HK) - The Certainties and the Uncertainties03 Jun 2021
- WuXi Biologics (2269 HK) - The Strength and the Potential Risk01 Apr 2021
- Presentation for Webinar: 2021 High Conviction-Investment Opportunities in China Healthcare Industry14 Jan 2021
- 2021 High Conviction - Investment Opportunities in China Healthcare Industry23 Nov 2020
x